Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

NCT03386513 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

179

Enrollment

INDUSTRY

Sponsor class

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm
Myeloproliferative Neoplasm

Interventions

DRUG: IMGN632

Sponsor

AbbVie